Sarcoma  >>  oxaliplatin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT00954876: Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer

Withdrawn
2
0
US
capecitabine and cetuximab
Translational Genomics Research Institute, Eli Lilly and Company
Metastatic Colorectal Cancer
01/10
01/10
NCT00819780 / 2008-004281-71: PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Checkmark ECC 2015
Sep 2015 - Sep 2015: ECC 2015
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark For 1st line treatment of mCRC pts with wild-type KRAS tumors
More
Completed
2
285
Europe, Canada, US
Panitumumab, Vectibix, Bevacizumab, Avastin, mFOLFOX6
Amgen
Colon Cancer, Colorectal Cancer, Rectal Cancer, Metastatic Colorectal Cancer
05/12
07/16
NCT01327612 / 2010-022270-14: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Completed
2
12
Europe, US
Modified FOLFOX6, Oxaliplatin-Leucovorin-Fluorouracil chemotherapy, Conatumumab, AMG 655, Ganitumab, AMG 479, Bevacizumab, Avastin
Amgen
Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced, Lymphoma, Metastatic Cancer, Non-Small Cell Lung Cancer, Sarcoma, Solid Tumors
02/20
02/20
Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Not yet recruiting
2
120
Europe
Dostarlimab, Chemotherapy
UNICANCER, National Cancer Institute, France, GlaxoSmithKline
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma
10/28
09/30
NCT03009058 / 2016-001459-28: Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Terminated
1/2
2
Europe
IMM-101, Heat killed M. obuense (NCTC) 13365), Gemcitabine, GEMZAR, Nabpaclitaxel, Abraxane, Capecitabine, Folinic Acid, Leucovorin, Fluorouracil, 5FU, Irinotecan, Campto, Camptosar, Oxaliplatin, Eloxatin, cetuximab, Erbitux, Anti-PD1, pembrolizumab (KEYTRUDA),, nivolumab (OPDIVO), Ipilimumab, YERVOY, Cyclophosphamide, cytophosphane
Immodulon Therapeutics Ltd
Metastatic Cancer
08/17
08/17

Download Options